Introduction: Hyperbilirubinemia in a neonate is one of the most common problems that may occur in 60-70 % of term and 80% of preterm babies. It is known to be associated with signi¿ cant morbidity like neonatal bilirubin encephalopathy and even death. Clinically, and almost exclusively ABO incompatibility occur in 'A' and 'B' blood group babies of O '+ve' mothers. These babies are reported to be at high risk of severe hyperbilirubinemia (serum bilirubin level more than 16 mg/dl). Objectives: To ¿ nd out the incidence of hyperbilirubinemia in babies born to 'O' positive mothers. To estimate the risk of ABO incompatibility in babies born to 'O' positive mothers. Materials and methods: A prospective cohort study conducted in B. P. Koirala institute of Health Science (Department of Pediatrics and Dept. of Gynae and Obstetric) from July 2002 to June 2003. A total of 199 women having 'O' positive blood group admitted to the Department of Gynae and Obstetric were included in the study. A piloted proforma was used to collect information. The blood group of neonates was tested by tile and slide method and serum bilirubin was estimated by diazo method in the Central Laboratory Services and Emergency laboratory of BPKIHS. The data was observed and analysis was carried out using statistical software SPSS-10. Results: Total 37 (18.5%) babies had developed hyperbilirubinemia and among them 14 (38%) were from group of babies having 'O' Positive blood group and 23 (62%) were from group of babies having other than 'O' Positive blood group. There was 2.6 times higher chance of having hyperbilirubinemia in the babies with ABO incompatibility than 'O' Positive babies after adjusting other signi¿ cant variables. Conclusion: Among different signi¿ cantly associated variables, ABO incompatibility was found to be a major risk factor for neonatal hyperbilirubinemia.It was seen that neonate with ABO incompatibility had two times higher chances of having hyperbilirubinemia than those babies with O '+ve' blood group. This ¿ nding in BPKIHS suggests that there is a need of screening cord blood bilirubin and continuous monitoring of bilirubin level in the hospital especially among ABO incompatible neonates.
H yperbilirubinemia in a neonate is one of the most vexing problems that may occur in 60-70 % of term and 80% of preterm babies 1 . It is known to be associated with signi¿ cant morbidity. In the neonatal period, it may result in bilirubin encephalopathy and even death 2 .
It may be entirely physiological or present as the ¿ rst sign of serious illness with associated toxicity manifested in the nervous system. Bilirubin encephalopathy in term and near term newborn is preventable. Excessive hyperbilirubinemia according to gestational age, if promptly identi¿ ed and appropriately treated provides prevention 3 .
Approximately 20% of all pregnancies are associated with ABO incompatibility between mother and the fetus 4 and only <10% of all these cases manifests ABO-Hemolytic diseases of the newborn (ABO-HDN). Clinically, and almost exclusively ABO incompatibility occur in 'A' and 'B' blood group babies of O '+ve' mothers. These babies are reported to be at high risk of severe hyperbilirubinemia (serum bilirubin level more than 16 mg/dl) 5 .
No such study has been conducted earlier in eastern part of Nepal. This study will help to develop a proper protocol for future management of neonatal hyperbilirubinemia in Nepal.
Aims and objectives
To ¿ nd out the incidence of hyperbilirubinemia 1.
in babies born to 'O' positive mothers.
To estimate the risk of ABO incompatibility in 2.
babies born to 'O' positive mothers.
Materials and methods
This is a prospective cohort study conducted in B. P. A piloted proforma was used to collect information. Blood groups of the newborns were identi¿ ed from cord blood sample. Serial serum bilirubin estimation was done from cord blood, at 24 hours, at 48 hours and at 72 hours. Those with more than 4 mg/dl at cord blood, > 10mg/dl at 24 hours, >12mg/dl at 48 hours and >15mg/ dl at 72 hours were considered as hyperbilirubinemia. The obtained data was entered into MS Excel and transferred to SPSS-10. The data were summarized using percentage. Association of hyperbilirubinemia was tested with different variables using Chi-square test.
To assess independent effect of signi¿ cant variables, a stepwise logistic regression method with maximum likelihood was used and adjusted Relative Risk was derived from logistic regression at Į=0.05.
BPKIHS research committee approved the study protocol. Informed consent was obtained from parents of all babies and study followed the rules laid down in the Helsinki declaration for research involving human subjects. (Table) Mothers age, ethnicity, gestational age, size of baby, birth weight, sepsis and blood group were signi¿ cantly associated with hyperbilirubinemia. However, after the logistic regression, blood group was the only signi¿ cant variable with hyperbilirubinemia. There was 2.6 times higher chance of having hyperbilirubinemia in the babies with ABO incompatibility than 'O' Positive babies after adjusting other signi¿ cant variables. (Table) Irrespective of blood group, pattern of development of hyperbilirubinemia is similar. Only the severity of jaundice is more in neonate having other than 'O' Positive blood group. On evaluation of cord blood bilirubin and serum bilirubin at 24 hrs,48hrs and 72hrs, comparatively higher level of bilirubin was seen in blood group other than 'O' Positive than in 'O' Positive blood group with statistical signi¿ cant p-value (p= 0.001). All 37 hyperbilirubinemic babies received phototherapy and altogether 11 (one from 'O' Positive and ten from other than 'O' Positive) babies who had higher level of bilirubin (>14mg/dl) even after 48 -72 hours of phototherapy required exchange transfusion. 6 . Contrast to the ¿ nding of this study, Ozolek et al had found hyperbilirubinemia with ABO-incompatibility in 6.9% babies only. However, Ozolek had involved all the mothers irrespective of their blood group in denominator hence reducing the actual incidence among 'O' Positive mothers.
Results
Our data con¿ rms the striking association between ABO-incompatibility and neonatal hyperbilirubinemia through a prospective cohort study. The chance of developing hyperbilirubinemia within 72 hours was 2.6 times higher in the babies with other blood group than the 'O' Positive babies after controlling other signi¿ cant variables through logistic regression. ABO incompatibility results in hemolysis. Bilirubin production is elevated because of increased breakdown of fetal erythrocytes. This is the result of the shortened lifespan of fetal erythrocytes and the higher erythrocyte mass in neonates. This ¿ nding is supported by earlier studies 7, 8, 6 . Similarly, Heier et al in their study on maternal blood group 'O' Positive as a risk factor of neonatal hyperbilirubinemia requiring treatment had found that ABO-incompatible babies born to 'O' Positive mothers has the double risk to develop jaundice requiring treatment and 5-10 times increased risk of exchange transfusion 9 .
In our study, ethnicity was signi¿ cantly associated with hyperbilirubinemia. However, this variable was insigni¿ cant after logistic regression. Ethnicity has been reported to be signi¿ cantly associated with neonatal hyperbilirubinemia. However, pathophysiology of ethnicity has not yet been explained 10 . Maternal age was statistically signi¿ cant in univariate analysis. However, logistic regression results showed that this variable was not associated with hyperbilirubinemia. This ¿ nding was similar with earlier studies from other parts of the world 11, 12, 13 .
Other factors such as gravida, gestational age, size of baby, male sex and sepsis were also signi¿ cant in univariate analysis but their effects were ruled out in logistic regression. These variables however were found to be signi¿ cant determinants of hyperbilirubinemia in neonates in earlier epidemiological study of neonatal hyperbilirubinemia 7 .
Breastfeeding has been reported to be a signi¿ cant risk factor for hyperbilirubinemia 14, 15, 16 . As BPKIHS is a baby friendly hospital, all the babies were initiated breastfeeding soon after delivery. Hence breast feeding as a risk factor for hyperbilirubinemia could not be ruled out in this study. Instrumental delivery and Maternal diabetes were also identi¿ ed risk factors for neonatal hyperbilirubinemia 17, 18 . All the babies were normal delivery. None of the mothers were diagnosed to have maternal diabetes. So, instrumental delivery and maternal diabetes were controlled due to restriction.
In our study, 1% of the respondents were discharged before 24 hours and 18% of the respondents were discharged after 48 hours. However, no readmission was reported of any study subjects. But, still we could have missed information of those babies who might have consulted other health centers after being discharged.
Management of hyperbilirubinemia in both term and preterm newborn were followed as per American Academy of Pediatrics (AAP) guidelines 19 .
Conclusion
Among different signi¿ cantly associated variables, ABO incompatibility was found to be a major risk factor for neonatal hyperbilirubinemia. It was seen that neonate with ABO incompatibility had two times higher chances of having hyperbilirubinemia than those babies with O '+ve' blood group. This ¿ nding in BPKIHS suggests that there is a need of screening cord blood bilirubin and continuous monitoring of bilirubin level in the hospital especially among ABO incompatible neonates.
